
Gezondheidsraad

Health Council of the Netherlands



Thomas J. Lentz, PhD, M.P.H.
Branch Chief
Document Development Branch
Education and Information Division
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health (NIOSH)
1090 Tusculum Avenue
Cincinnati, OH 45226-1998
USA

Subject : Comments on Adriamycin
Your reference : September 12, 2014, Letter + Comments on Adriamycin
Our reference : I-1582/BvdV/cn/459-V71
Enclosure(s) : 2
Date : March 18, 2015

Dear dr. Lentz,

Thank you and your colleagues dr. T. Connor and dr L. Rojanasakul for accepting the invitation to comment on the draft report 'Adriamycin', which was published for public review in June 2014 by the Dutch Expert Committee on Occupational Safety (DECOS) of the Health Council of the Netherlands.

The Committee highly appreciates the detailed comments presented by the NIOSH reviewers. The Committee has incorporated quite a number of the recommended references in its final report. Especially the studies regarding the occupational exposure of adriamycin were considered important (Pieri et al., Kauppinen et al.) The Committee has shown some reluctance to elaborate on studies that were too obviously concerned with therapeutic and clinical aspects of adriamycin and made a selection from the recommended studies. Most of the studies on the genotoxic mechanisms were included as reference, but the Committee did not choose for a detailed discussion in the report.

In the Annex to this letter the responses by DECOS to all recommendations made by NIOSH are specified.

P.O. Box 16052
NL-2500 BB The Hague
The Netherlands
Telephone +31 (70) 340 74 47
E-mail: b.v.d.voet@gr.nl

Visiting Address
Rijnstraat 50
NL-2515 XP The Hague
The Netherlands
www.gr.nl



Subject : Comments on Adriamycin
Our reference : I-1582/bvdV/cn/459-V71
Page : 2
Date : March 18, 2015

Enclosed you find a copy of the final report on 'Adriamycin'.

Yours sincerely,

G.B. van der Voet, PhD, ERT
Scientific secretary

Enclosures:

Detailed response by DECOS to NIOSH comments
Final report on 'Adriamycin'